Last reviewed · How we verify

NCT06778343: BIRDD

Biomarkers in Inflammatory Rheumatic Diseases Diagnosis

Recruiting now Last updated 20 January 2025
What this trial tests

trial in Ankylosing Spondylitis in 134 participants. Currently enrolling.

Timeline
31 January 2023
Primary endpoint
31 March 2025
30 June 2025

Quick facts

Lead sponsorUniversidade Nova de Lisboa
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment134
Start date31 January 2023
Primary completion31 March 2025
Estimated completion30 June 2025
Sites1 location across Portugal

Conditions studied

Sponsor

Universidade Nova de Lisboa — full company profile →

Who can join

Adults 18 to 65, any sex, with Ankylosing Spondylitis or Rheumatic Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ankylosing spondylitis (AS), Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) are three diseases where early diagnosis remains a major challenge. However, early diagnosis is the main determinant for a better prognosis. In the early stage, symptoms may be nonspecific and often difficult to establish a differential diagnosis between rheumatic diseases and other diseases, namely infectious and cancer diseases.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Ankylosing Spondylitis

Currently open trials in the same condition.

Other Universidade Nova de Lisboa trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06778343.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing